GlassScriptPhysician profile
Sara L Perry
NPI 1871684423
$9,361.38
in general payments reported to CMS, 2019-2025
62 companies · $3,548 in 2025
The $3,548 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $291 · 2023: $1,804 · 2024: $3,718 · 2025: $3,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,695 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,695.23 |
| Education | $374.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $741.71 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $711.38 | 2022-2025 | Calquence, Tagrisso, Lynparza |
| Daiichi Sankyo INC. | $622.78 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $562.57 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $508.23 | 2023-2025 | Libtayo |
| Janssen Biotech, INC. | $443.79 | 2022-2025 | Rybrevant, Darzalex, Talvey |
| Incyte Corporation | $421.35 | 2022-2025 | Monjuvi, Jakafi, Pemazyre |
| Celgene Corporation | $337.19 | 2022-2025 | Reblozyl, Pomalyst |
| Genzyme Corporation | $298.90 | 2022-2025 | |
| Gilead Sciences, INC. | $249.67 | 2022-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $241.15 | 2023-2025 | Ninlaro, Iclusig |
| Exelixis INC. | $208.01 | 2022-2025 | Cabometyx |
| Tersera Therapeutics LLC | $199.37 | 2022-2025 | Zoladex, Xermelo |
| Eisai INC. | $192.43 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $174.00 | 2023-2025 | Fotivda |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $169.43 | 2022-2025 | Opdualag, Opdivo, Krazati |
| Lilly USA, LLC | $164.46 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Emd Serono, INC. | $156.56 | 2023-2025 | Bavencio |
| Jazz Pharmaceuticals INC. | $155.45 | 2022-2025 | |
| Genentech USA, INC. | $147.69 | 2023-2025 | Tecentriq, Venclexta, Itovebi |
| Bayer Healthcare Pharmaceuticals INC. | $140.49 | 2023-2025 | |
| Pfizer INC. | $138.82 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $134.84 | 2023-2025 | Ultomiris |
| Astellas Pharma US INC | $132.08 | 2023-2025 | Padcev |
| Ipsen Biopharmaceuticals, INC | $129.46 | 2024-2025 | Onivyde |
| Genmab U.S., INC. | $121.34 | 2024-2025 | Epkinly |
| Abbvie INC. | $120.99 | 2024 | |
| Mirati Therapeutics, INC. | $118.26 | 2023-2024 | Krazati |
| Kite Pharma, INC. | $116.34 | 2024 | |
| Deciphera Pharmaceuticals INC. | $104.14 | 2024-2025 | Qinlock, Romvimza |
| Puma Biotechnology, INC. | $102.56 | 2022-2025 | |
| Taiho Oncology, INC. | $98.82 | 2023-2025 | |
| Shield Therapeutics INC | $77.74 | 2024 | |
| Pharmacosmos Therapeutics INC. | $76.96 | 2024-2025 | Monoferric, Cosela |
| Beigene USA, INC. | $70.34 | 2023-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $68.08 | 2024 | Tavalisse, Rezlidhia |
| Adc Therapeutics America, INC. | $65.84 | 2024-2025 | |
| Array Biopharma INC | $58.93 | 2023-2025 | Mektovi, Braftovi, Xalkori |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.36 | 2025 | Gilotrif |
| Seagen INC. | $55.08 | 2023 | Tukysa, Padcev |
| Sobi, INC | $54.19 | 2025 | |
| Morphosys, US INC. | $53.75 | 2023 | Monjuvi |
| Blueprint Medicines Corporation | $43.88 | 2024 | Ayvakit |
| Janssen Pharmaceuticals, INC | $43.45 | 2024 | Xarelto |
| Caris Mpi, INC. | $41.78 | 2025 | Mi Cancer Seek |
| Legend Biotech USA INC. | $40.70 | 2025 | Carvykti |
| Glaxosmithkline, LLC. | $40.55 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Pharmaessentia USA Corporation | $40.06 | 2024 | Besremi |
| Karyopharm Therapeutics INC. | $38.82 | 2024-2025 | Xpovio |
| Kyowa Kirin, INC. | $29.65 | 2024 | Poteligeo |
| Verity Pharmaceuticals INC. | $27.94 | 2024 | Trelstar |
| Sun Pharmaceutical Industries INC. | $26.04 | 2024 | |
| Geron Corporation | $23.55 | 2025 | Rytelo |
| Organon LLC | $23.19 | 2023 | Ontruzant |
| Progenics Pharmaceuticals, INC. | $21.41 | 2023 | Pylarify |
| Agios Pharmaceuticals, INC. | $20.25 | 2025 | Pyrukynd |
| Syndax Pharmaceuticals, INC. | $20.01 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $18.37 | 2023 | Imbruvica |
| Cti Biopharma Corp. | $17.36 | 2023 | Vonjo |
| Fennec Pharmaceuticals, INC. | $15.43 | 2025 | Fyarro |
| Cycle Pharmaceuticals INC | $14.47 | 2025 | Phyrago |
| Amgen INC. | $13.94 | 2023 | Nplate, Xgeva, Vectibix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.